List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. Asia Pacific Drug Discovery Market, 2019-2030, $ mn 19
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Drug Discovery Market 25
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 29
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 29
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Drug Discovery Market 32
Figure 10. Investment Opportunity Analysis 36
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Drug Discovery Market 39
Figure 12. Breakdown of Asia Pacific Drug Discovery Market by Drug Type, 2019-2030, % of Revenue 44
Figure 13. Asia Pacific Addressable Market Cap in 2021-2030 by Drug Type, Value ($ mn) and Share (%) 44
Figure 14. Asia Pacific Drug Discovery Market by Drug Type: Small Molecule Drugs, 2019-2030, $ mn 45
Figure 15. Asia Pacific Drug Discovery Market by Drug Type: Biologic Drugs, 2019-2030, $ mn 46
Figure 16. Breakdown of Asia Pacific Drug Discovery Market by Service, 2019-2030, % of Sales Revenue 48
Figure 17. Asia Pacific Addressable Market Cap in 2021-2030 by Service, Value ($ mn) and Share (%) 48
Figure 18. Asia Pacific Drug Discovery Market by Service: Medicinal Chemical Services, 2019-2030, $ mn 49
Figure 19. Asia Pacific Drug Discovery Market by Service: Biological Services, 2019-2030, $ mn 50
Figure 20. Asia Pacific Drug Discovery Market by Service: Drug Metabolism and Pharmacokinetics (DMPK) Services, 2019-2030, $ mn 51
Figure 21. Asia Pacific Drug Discovery Market by Service: Other Pharmaceutical Services, 2019-2030, $ mn 52
Figure 22. Breakdown of Asia Pacific Drug Discovery Market by Process, 2019-2030, % of Sales Revenue 54
Figure 23. Asia Pacific Addressable Market Cap in 2021-2030 by Process, Value ($ mn) and Share (%) 54
Figure 24. Asia Pacific Drug Discovery Market by Process: Target Selection, 2019-2030, $ mn 55
Figure 25. Asia Pacific Drug Discovery Market by Process: Target Validation, 2019-2030, $ mn 56
Figure 26. Asia Pacific Drug Discovery Market by Process: Hit-To-Lead Identification, 2019-2030, $ mn 57
Figure 27. Asia Pacific Drug Discovery Market by Process: Lead Optimization, 2019-2030, $ mn 58
Figure 28. Asia Pacific Drug Discovery Market by Process: Candidate Validation, 2019-2030, $ mn 59
Figure 29. Breakdown of Asia Pacific Drug Discovery Market by Technology, 2019-2030, % of Revenue 61
Figure 30. Asia Pacific Addressable Market Cap in 2021-2030 by Technology, Value ($ mn) and Share (%) 61
Figure 31. Asia Pacific Drug Discovery Market by Technology: High Throughput Screening, 2019-2030, $ mn 62
Figure 32. Asia Pacific Drug Discovery Market by Technology: Combinatorial Chemistry, 2019-2030, $ mn 63
Figure 33. Asia Pacific Drug Discovery Market by Technology: Pharmacogenomics and Pharmacogenetics, 2019-2030, $ mn 64
Figure 34. Asia Pacific Drug Discovery Market by Technology: Nanotechnology, 2019-2030, $ mn 65
Figure 35. Asia Pacific Drug Discovery Market by Technology: Bioanalytical Instruments, 2019-2030, $ mn 66
Figure 36. Asia Pacific Drug Discovery Market by Technology: Biochips, 2019-2030, $ mn 67
Figure 37. Asia Pacific Drug Discovery Market by Technology: Bioinformatics, 2019-2030, $ mn 68
Figure 38. Asia Pacific Drug Discovery Market by Technology: Other Technologies, 2019-2030, $ mn 69
Figure 39. Breakdown of Asia Pacific Drug Discovery Market by Therapeutic Area, 2019-2030, % of Revenue 71
Figure 40. Asia Pacific Addressable Market Cap in 2021-2030 by Therapeutic Area, Value ($ mn) and Share (%) 71
Figure 41. Asia Pacific Drug Discovery Market by Therapeutic Area: Oncology, 2019-2030, $ mn 72
Figure 42. Asia Pacific Drug Discovery Market by Therapeutic Area: Neurology, 2019-2030, $ mn 73
Figure 43. Asia Pacific Drug Discovery Market by Therapeutic Area: Infectious and Immune System Diseases, 2019-2030, $ mn 74
Figure 44. Asia Pacific Drug Discovery Market by Therapeutic Area: Digestive System Diseases, 2019-2030, $ mn 75
Figure 45. Asia Pacific Drug Discovery Market by Therapeutic Area: Cardiovascular Diseases, 2019-2030, $ mn 76
Figure 46. Asia Pacific Drug Discovery Market by Therapeutic Area: Diabetes, 2019-2030, $ mn 77
Figure 47. Asia Pacific Drug Discovery Market by Therapeutic Area: Respiratory Disease, 2019-2030, $ mn 78
Figure 48. Asia Pacific Drug Discovery Market by Therapeutic Area: Other Therapeutic Areas, 2019-2030, $ mn 79
Figure 49. Breakdown of Asia Pacific Drug Discovery Market by End User, 2019-2030, % of Revenue 80
Figure 50. Asia Pacific Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%) 81
Figure 51. Asia Pacific Drug Discovery Market by End User: Pharmaceutical Companies, 2019-2030, $ mn 82
Figure 52. Asia Pacific Drug Discovery Market by End User: Contract Research Organizations (CROs), 2019-2030, $ mn 83
Figure 53. Asia Pacific Drug Discovery Market by End User: Research Institutes, 2019-2030, $ mn 84
Figure 54. Asia Pacific Drug Discovery Market by End User: Other End Users, 2019-2030, $ mn 85
Figure 55. Breakdown of APAC Drug Discovery Market by Country, 2019 and 2030, % of Revenue 87
Figure 56. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 88
Figure 57. Drug Discovery Market in Japan, 2019-2030, $ mn 90
Figure 58. Drug Discovery Market in China, 2019-2030, $ mn 92
Figure 59. Drug Discovery Market in Australia, 2019-2030, $ mn 94
Figure 60. Drug Discovery Market in India, 2019-2030, $ mn 96
Figure 61. Drug Discovery Market in South Korea, 2019-2030, $ mn 98
Figure 62. Drug Discovery Market in Rest of APAC, 2019-2030, $ mn 100
Figure 63. Growth Stage of Asia Pacific Drug Discovery Industry over the Forecast Period 102
Asia Pacific drug discovery market will grow by 10.6% annually with a total addressable market cap of $231.8 billion over 2021-2030 owing the rising demand for specialty medicines, the surge in lifestyle-oriented diseases and the advancements in technology, the growing elderly population and the rising healthcare expenses, rising expenditure on R&D, and expiration of patents. Highlighted with 33 tables and 63 figures, this 120-page report “Asia Pacific Drug Discovery Market 2020-2030 by Drug Type (Small Molecule, Biologics), Service (Medicinal, Biological, DMPK), Process, Technology, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific drug discovery market in every aspect of the classification from perspectives of Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Country. Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Small Molecule Drugs • Biologic Drugs Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Medicinal Chemical Services • Biological Services • Drug Metabolism and Pharmacokinetics (DMPK) Services • Other Pharmaceutical Services Based on Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Target Selection • Target Validation • Hit-To-Lead Identification • Lead Optimization • Candidate Validation Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • High Throughput Screening • Combinatorial Chemistry • Pharmacogenomics and Pharmacogenetics • Nanotechnology • Bioanalytical Instruments • Biochips • Bioinformatics • Other Technologies Based on Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Oncology • Neurology • Infectious and Immune System Diseases • Digestive System Diseases • Cardiovascular Diseases • Diabetes • Respiratory Disease • Other Therapeutic Areas Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Pharmaceutical Companies • Contract Research Organizations (CROs) • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Drug Type, Service, and Therapeutic Area over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Inc. Agilent Technologies Inc. Astrazeneca plc Bayer AG Charles River Laboratories International Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd GlaxoSmithKline PLC Merck & Co. Inc. Novartis AG Pfizer Inc. Shimadzu Corp Thermo Fisher Scientific Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More